Bioequivalence Study of Minocycline 100mg Tablets Under Fasting Conditions

NCT00776542 | Completed DMC

• 1 other identifier: AAI-US-134
• Study Type: interventional
• Target: 28
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study was to determine the bioequivalence of Minocycline formulations after administration of single doses to normal healthy subjects under fasted conditions. These data were to be evaluated statistically to determine if the products meet bioequivalence criteria.

Conditions

Healthy

Keywords

bioequivalence Minocycline Tablets

Outcome Measures

Primary Outcomes (1)

• Bioequivalence

Study Arms (2)

1

EXPERIMENTAL

Minocycline 100 mg tablets of ranbaxy

Drug: Minocycline 100mg Tablets

2

ACTIVE COMPARATOR

Minocin 100mg tablets

Drug: Minocycline 100mg Tablets

Interventions

Minocycline 100mg Tablets DRUG

1; 2

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy males and females between 18 and 45 years of age inclusive.
• Informed o'f the nature of the study and given written informed consent.
• Have a body weight within 15 % of the appropriate range as defined in the 1983 Metropolitan Life Company tables and weighing at least 100 lbs.

You may not qualify if:

• Hypersensitivity to Minocycline (Minocin®), or other antibiotics.
• Any history of a clinical condition which might affect drug absorption, metabolism or excretion.
• Recent history of mental illness, drug addiction, drug abuse or alcoholism.
• Donation of greater than 500 ml of blood in the past 4 weeks prior to study dosing or difficulty in donating blood.
• Received an investigational drug within the 4 weeks prior to study dosing.
• Currently taking any prescription medication, except oral contraceptives, within the 7 days pr/or to study dosing or over-the-counter medication within 3 days of study dosing. This prohibitor\~ does not include vitamins or herbal preparations taken as nutritional supplements for non-therapeutic indications as judged by the attending physic/an2
• Tobacco use (\>5 cigarettes per day) in the 3 months prior to study dosing.
• If female, the subject is lactating or has a positive pregnancy test at screening and prior to each of the two treatment periods.
• Females of child bearing potential must use a 'medically acceptable method of contraception throughout the entire study period and for one week after the study is completed.
• Medically acceptable methods of contraception that may be used by the subject and/or her partner are: oral contraceptives, progestin injection' or implants, condom with spermicide, diaphragm with spermicide, IUD, vaginal spermicidal suppository, surgical sterilization of their partner(s) or abstinence.
• Females taking oral contraceptives must have taken them consistently for at least three months prior to receiving study medication.

Sponsors & Collaborators

• Ranbaxy Laboratories Limited: lead

Study Sites (1)

AII pharma

Chapell Hill, North Carolina, 27514, United States

Location

Related Links

• Related Info
• Related Info
• Related Info

MeSH Terms

Interventions

Minocycline

Intervention Hierarchy (Ancestors)

Tetracyclines; Naphthacenes; Polycyclic Aromatic Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Polycyclic Compounds

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: October 20, 2008
• First Posted: October 21, 2008
• Study Start: October 1, 2002
• Primary Completion: November 1, 2002
• Study Completion: January 1, 2003
• Last Updated: October 21, 2008

Record last verified: 2008-10

Locations

US (1)